SGYP: With a $.85 billion market cap, this now seems a little rich as the sales ramp will be slow but steady. After all, this isn't a cancer drug. I think many are thinking this is a buyout scenario. Management has made little movement (that I'm aware of) towards setting up a sales infrastructure.